{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:26:57Z","timestamp":1793647617869,"version":"4.5.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Innovent Biologics (Suzhou) Co., Ltd","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01651-5","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T01:57:32Z","timestamp":1735610252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia\/Ib study"],"prefix":"10.1186","volume":"17","author":[{"given":"Chenyu","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixiang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"1651_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"1651_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L. Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annu Rev Immunol. 2022;40:45\u201374.","journal-title":"Annu Rev Immunol"},{"key":"1651_CR3","doi-asserted-by":"crossref","unstructured":"Borgeaud M, Sandoval J, Obeid M, Banna G, Michielin O, Addeo A et al. Novel targets for immune-checkpoint inhibition in cancer. Cancer Treatment Reviews [Internet]. 2023 [cited 2023 Dec 5];120. https:\/\/www.cancertreatmentreviews.com\/article\/S0305-7372(23)00107-X\/fulltext","DOI":"10.1016\/j.ctrv.2023.102614"},{"key":"1651_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16:101.","journal-title":"J Hematol Oncol"},{"key":"1651_CR5","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023;24:1415\u201322.","journal-title":"Nat Immunol"},{"key":"1651_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13578-023-01073-9","volume":"13","author":"B Wang","year":"2023","unstructured":"Wang B, Han Y, Zhang Y, Zhao Q, Wang H, Wei J, et al. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms. Cell Biosci. 2023;13:120.","journal-title":"Cell Biosci"},{"key":"1651_CR7","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy\u2014current perspectives and future directions. Cell. 2023;186:1652\u201369.","journal-title":"Cell"},{"key":"1651_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jtho.2017.01.019","volume":"12","author":"Y He","year":"2017","unstructured":"He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, et al. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1\/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol. 2017;12:814\u201323.","journal-title":"J Thorac Oncol"},{"key":"1651_CR9","doi-asserted-by":"publisher","first-page":"e001014","DOI":"10.1136\/jitc-2020-001014","volume":"8","author":"T Maruhashi","year":"2020","unstructured":"Maruhashi T, Sugiura D, Okazaki I-M, Okazaki T. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020;8:e001014.","journal-title":"J Immunother Cancer"},{"key":"1651_CR10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","volume":"82","author":"J Paik","year":"2022","unstructured":"Paik J. Nivolumab Plus Relatlimab: First Approval. Drugs. 2022;82:925\u201331.","journal-title":"Drugs"},{"key":"1651_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386:24\u201334.","journal-title":"N Engl J Med"},{"key":"1651_CR12","doi-asserted-by":"publisher","first-page":"e003776","DOI":"10.1136\/jitc-2021-003776","volume":"10","author":"P Sch\u00f6ffski","year":"2022","unstructured":"Sch\u00f6ffski P, Tan DSW, Mart\u00edn M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, et al. Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525)\u2009\u00b1\u2009anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer. 2022;10:e003776.","journal-title":"J Immunother Cancer"},{"key":"1651_CR13","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.esmoop.2022.100639","volume":"7","author":"E Garralda","year":"2022","unstructured":"Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im S-A, et al. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022;7:100639.","journal-title":"ESMO Open"},{"key":"1651_CR14","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-23-2396","volume":"30","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Hu Z, Bathena SP, Keidel S, Miller-Moslin K, Statkevich P, et al. Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors. Clin Cancer Res. 2024;30:3050\u20138.","journal-title":"Clin Cancer Res"},{"key":"1651_CR15","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3390\/jpm11070651","volume":"11","author":"A Botticelli","year":"2021","unstructured":"Botticelli A, Zizzari IG, Scagnoli S, Pomati G, Strigari L, Cirillo A, et al. The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. JPM. 2021;11:651.","journal-title":"JPM"},{"key":"1651_CR16","doi-asserted-by":"publisher","first-page":"153303382312026","DOI":"10.1177\/15330338231202650","volume":"22","author":"Y Li","year":"2023","unstructured":"Li Y, Wang W, Tian J, Zhou Y, Shen Y, Wang M, et al. Clinical Significance of Soluble LAG-3 (sLAG-3) in Patients With Cervical Cancer Determined via Enzyme-Linked Immunosorbent Assay With Monoclonal Antibodies. Technol Cancer Res Treat. 2023;22:15330338231202650.","journal-title":"Technol Cancer Res Treat"},{"key":"1651_CR17","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1200\/JCO.22.02072","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, et al. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti\u2013Programmed Death-1\/Programmed Death Ligand 1 Therapy: Results From the Phase I\/IIa RELATIVITY-020 Trial. JCO. 2023;41:2724\u201335.","journal-title":"JCO"},{"key":"1651_CR18","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002\u201314.","journal-title":"Lancet"},{"key":"1651_CR19","doi-asserted-by":"publisher","first-page":"EVIDoa2200239","DOI":"10.1056\/EVIDoa2200239","volume":"2","author":"GV Long","year":"2023","unstructured":"Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, et al. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evid. 2023;2:EVIDoa2200239.","journal-title":"NEJM Evid"},{"key":"1651_CR20","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","volume":"187","author":"LP Andrews","year":"2024","unstructured":"Andrews LP, Butler SC, Cui J, Cillo AR, Cardello C, Liu C, et al. LAG-3 and PD-1 synergize on CD8\u2009+\u2009T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity. Cell. 2024;187:4355\u2013e437222.","journal-title":"Cell"},{"key":"1651_CR21","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","volume":"187","author":"AR Cillo","year":"2024","unstructured":"Cillo AR, Cardello C, Shan F, Karapetyan L, Kunning S, Sander C, et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8\u2009+\u2009T cells to promote antitumor immunity. Cell. 2024;187:4373\u2013e438815.","journal-title":"Cell"},{"key":"1651_CR22","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, et al. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). J Thorac Oncol. 2021;16:1501\u201311.","journal-title":"J Thorac Oncol"},{"key":"1651_CR23","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial. JAMA. 2023;330:2064\u201374.","journal-title":"JAMA"},{"key":"1651_CR24","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.23.01636","volume":"42","author":"S Hegewisch-Becker","year":"2024","unstructured":"Hegewisch-Becker S, Mendez G, Chao J, Nemecek R, Feeney K, Van Cutsem E, et al. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study. J Clin Oncol. 2024;42:2080\u201393.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01651-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01651-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01651-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T02:07:16Z","timestamp":1735610836000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01651-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1651"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01651-5","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review board and ethics committee of all participating sites. This study was registered at clinicaltrials.gov (NCT04085185) and conducted following Good Clinical Practice Guidelines, the Declaration of Helsinki, and relevant local regulatory policy. Written informed consents were required before patient enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}